Liminal BioSciences Inc. Company Profile

Background

Overview

Liminal BioSciences Inc. is a development-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that modulate G protein-coupled receptor (GPCR) pathways. The company aims to address significant unmet medical needs in metabolic, inflammatory, and fibrotic diseases through its integrated drug discovery platform and medicinal chemistry expertise.

Mission and Vision

Liminal BioSciences is dedicated to advancing healthcare by developing innovative therapies targeting complex biological mechanisms. The company's mission is to create best-in-class therapeutics that improve patient outcomes in areas with high unmet medical needs.

Primary Area of Focus

The company's primary focus is on the discovery and development of small molecule drugs that modulate GPCR pathways, specifically targeting diseases such as idiopathic pulmonary fibrosis (IPF), eosinophil-driven diseases, and other metabolic, inflammatory, and fibrotic conditions.

Industry Significance

Liminal BioSciences operates in the biopharmaceutical industry, contributing to the development of novel therapies for complex diseases. Its focus on GPCR pathways positions it within a specialized segment of the pharmaceutical sector, addressing areas with significant unmet medical needs.

Key Strategic Focus

Core Objectives

Therapeutic Development: Advance the development of small molecule therapeutics targeting GPCR pathways to treat metabolic, inflammatory, and fibrotic diseases.

Pipeline Expansion: Broaden the company's research and development pipeline with novel preclinical programs and potential first-in-class drug candidates.

Specific Areas of Specialization

GPCR Modulation: Design and develop small molecules that modulate GPCR pathways, leveraging a deep understanding of GPCR biology.

Disease Focus: Target diseases such as IPF, eosinophil-driven diseases, and other conditions with significant unmet medical needs.

Key Technologies Utilized

Integrated Drug Discovery Platform: Utilize a comprehensive platform combining medicinal chemistry and in vivo capabilities to identify and develop therapeutic candidates.

GPCR Biology Expertise: Apply extensive knowledge of GPCR biology to inform drug discovery and development processes.

Primary Markets or Conditions Targeted

Metabolic Diseases: Address conditions like IPF and other metabolic disorders.

Inflammatory Diseases: Develop therapies for diseases characterized by inflammation.

Fibrotic Diseases: Target conditions involving tissue fibrosis, such as IPF.

Financials and Funding

Funding History

Liminal BioSciences has undergone significant financial developments, including a definitive arrangement agreement with Structured Alpha LP (SALP), a limited partnership managed by Thomvest Asset Management Ltd., under which SALP will acquire all outstanding common shares of the company at a significant premium. This transaction is expected to close by the end of September 2023, pending necessary approvals and conditions.

Total Funds Raised

The company has raised a total of $8.5 million over four funding rounds, with the latest round completed on April 10, 2025.

Notable Investors

Structured Alpha LP (SALP), managed by Thomvest Asset Management Ltd., is a significant investor, as evidenced by the proposed acquisition.

Intended Utilization of Capital

The capital raised is intended to support the advancement of Liminal BioSciences' R&D pipeline, including the development of novel therapeutics targeting GPCR pathways, and to facilitate the proposed acquisition by SALP.

Pipeline Development

Key Pipeline Candidates

LMNL6511: A selective antagonist for the GPR84 receptor, expected to commence a Phase 1 clinical trial in the second half of 2023.

LMNL6326: An antagonist for the OXER1 receptor, targeting eosinophil-driven diseases, currently in preclinical development.

GPR40 Agonists: A series of compounds targeting the GPR40 receptor, in preclinical stages.

Stages of Clinical Trials or Product Development

LMNL6511: Anticipated to enter Phase 1 clinical trials in the latter half of 2023.

LMNL6326 and GPR40 Agonists: Currently in preclinical development stages.

Target Conditions

LMNL6511: Metabolic diseases, particularly IPF.

LMNL6326: Eosinophil-driven diseases.

GPR40 Agonists: Metabolic disorders.

Relevant Timelines for Anticipated Milestones

LMNL6511: Phase 1 clinical trial initiation in the second half of 2023.

Technological Platform and Innovation

Proprietary Technologies

Integrated Drug Discovery Platform: Combines medicinal chemistry and in vivo capabilities to identify and develop therapeutic candidates.

Significant Scientific Methods

GPCR Modulation: Designing small molecules that modulate GPCR pathways to treat complex diseases.

Leadership Team

Key Executive Profiles

Pierre Laurin: Founder and CEO of Liminal BioSciences, with extensive experience in biopharmaceuticals and a deep understanding of GPCR biology.

Key Contributions or Roles Within the Company

Pierre Laurin: Leads the company's strategic direction and oversees the development of its R&D pipeline.

Leadership Changes

Recent Significant Changes or Appointments

As of the latest available information, there have been no recent significant changes or appointments within the company's leadership.

Competitor Profile

Market Insights and Dynamics

Liminal BioSciences operates in the biopharmaceutical industry, focusing on novel therapeutics for complex diseases. The market for such therapies is characterized by high unmet medical needs and significant competition from both established pharmaceutical companies and emerging biotech firms.

Competitor Analysis

Alkahest: A biotechnology company focusing on plasma-derived therapeutics, generating $12.6 million more revenue than Liminal BioSciences.

Diploma: A company in the construction supplies and fittings industry, with 3,346 more employees than Liminal BioSciences.

Verge Genomics: A biotechnology company headquartered in South San Francisco, generating 3,871% more revenue than Liminal BioSciences.

Strategic Collaborations and Partnerships

The proposed acquisition by Structured Alpha LP (SALP), managed by Thomvest Asset Management Ltd., is a significant strategic move, potentially providing additional resources and expertise to advance Liminal BioSciences' R&D initiatives.

Operational Insights

Liminal BioSciences' focus on GPCR pathways and its integrated drug discovery platform provide a competitive edge in developing novel therapeutics for complex diseases. The company's strategic direction, including the proposed acquisition, aims to strengthen its market position and enhance its innovation capacity.

Strategic Opportunities and Future Directions

The anticipated Phase 1 clinical trial for LMNL6511 in the latter half of 2023 represents a significant milestone. The proposed acquisition by SALP may also open new avenues for growth and development, potentially expanding the company's capabilities and market reach.